Viridian Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $86 | $72 | $72 | $72 |
Gross Profit | 86 | -5,719 | -273 | -278 |
EBITDA | -75,555 | -63,854 | -47,610 | -65,594 |
EBIT | -75,685 | -63,996 | -47,955 | -65,944 |
Net Income | -76,689 | -64,992 | -48,542 | -66,860 |
Net Change In Cash | 86 | 72 | 72 | 72 |
Free Cash Flow | -67,999 | -46,162 | -45,223 | -38,048 |
Cash | 200,317 | 107,667 | 91,641 | 102,827 |
Basic Shares | 66,420 | 63,854 | 61,099 | 49,681 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $314 | $1,772 | $2,963 | $1,050 |
Gross Profit | -1,008 | 1,017 | 2,343 | -27,254 |
EBITDA | -234,565 | -128,633 | -78,790 | -109,668 |
EBIT | -235,087 | -129,388 | -79,410 | -110,207 |
Net Income | -237,734 | -125,444 | -79,416 | -110,984 |
Net Change In Cash | 314 | 1,772 | 2,963 | 1,050 |
Cost of Revenue | 113,280 | -3,598 | 21,051 | |
Free Cash Flow | -185,068 | -94,635 | -54,919 | -29,821 |
Cash | 102,827 | 155,579 | 42,299 | 45,897 |
Basic Shares | 44,755 | 32,087 | 11,918 | 3,557 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$1.15 |
2024-06-30 | -$1.02 |
2024-03-31 | -$0.79 |
2023-12-31 | -$1.35 |
